Tuesday, April 16, 2024

Three-dose of Chinese vaccine against COVID-19 has been approved for human trials in Pakistan

Starting next week, Pakistan will start Phase III of another Chinese vaccine called ZF2001

DRAP gives the green light to run tests on the ZF2001

A UHS spokesman said the vaccine would be given to 10,000 participants in the third phase of the study.

Another Chinese coronavirus vaccine has been approved for human trials in Pakistan. Studies begin next week with an enrollment of adult volunteers.

So far, Pakistan has given emergency agreement for four anti-coronavirus vaccines – Britain’s AstraZeneca, Russia’s Sputnik-V, China’s Sinopharmand, China’s CanSino Sting.

A company spokesman said on Sunday that Chughtai’s laboratory would soon have Russia’s Sputnik V vaccine from Covid-19. To sell commercially. This made Pakistan one of the first countries to publish photos on the private market due to difficulties in securing supplies.

Despite concerns about fairness and higher prices, Islamabad agreed this week to allow commercial import and sale of vaccines without price caps. Unlike most countries that import and distribute vaccines through government channels.

Produced by CanSino Biologics, the single-dose Ad5-nCoV vaccine was tested in more than 18,000 volunteers across the country from September to January in Pakistan.

Read more: UHS begins testing another coronavirus vaccine from China next week

Phase III human trial

Now, starting next week, Pakistan will start Phase III human trials of another Chinese vaccine called ZF2001, said the University of Health Sciences, said Lahore Vice Chancellor Javed Akram.

The Pakistani Drug Regulatory Authority has given the green light to conduct a study on ZF2001. A drug jointly developed by Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd. and the Institute of Microbiology of the Chinese Academy of Sciences.

Dr. Shehnoor Azhar, spokesman for UHS, also confirmed, adding that while most vaccines require a dose or two, ZF2001 is a threefold shot.

In the third phase of the study, he continued, the vaccine given to 10,000 participants at UHS. The National Defense Hospital in Lahore and the Aga Khan Hospital in Karachi.

Latest news